Filing summary
Identity and period: The supplied filing text is for Dataram Corporation and its subsidiaries—not U.S. Gold Corp. It is a Form 10-Q for the quarter ended July 31, 2011 (Dataram fiscal 2012 first quarter), with results compared with the three months ended July 31, 2010. This conflicts with the request metadata identifying U.S. Gold Corp. and “2011 Q1.”
Financial performance
- Revenue: $10.27 million, down 19.4% from $12.74 million. Management attributed the decline mainly to lower average selling prices as DRAM chip prices fell approximately 24% year over year.
- Profit and margins: Gross profit was approximately $2.89 million, or 28.2% of revenue, versus $3.12 million, or 24.5%, in the prior-year quarter. Operating loss was $740,192 (7.2% of revenue), compared with $1.13 million (8.9%). Net loss was $853,957, or $0.08 per share, versus $1.24 million, or $0.14 per share.
- Expenses: Selling, general and administrative expense rose to $3.45 million from $3.08 million, primarily due to XcelaSAN sales and marketing. Engineering expense fell to $181,436 from $274,562. Reported research and development expense was zero versus $894,349; the company capitalized $632,638 of software development costs in the quarter.
- Cash flow: Operating activities used $572,144; investing activities used $895,069, including $632,638 of software development and $205,067 of property and equipment additions. Financing activities provided $1.87 million, principally from the equity offering, partly offset by $1.13 million of revolving-credit repayments. Cash increased $401,590 to $746,695.
- Liquidity and debt: Working capital was approximately $4.72 million and the current ratio 1.9, versus $3.13 million and 1.4 at April 30, 2011. Current liabilities included $1.02 million on a bank revolving line and $1.50 million due under a related-party inventory consignment financing arrangement. The bank facility had approximately $1.39 million of additional availability; no further financing was then available under the consignment arrangement. The company reported compliance with bank covenants.
- Capital and dilution: A May 2011 registered direct offering of 1.775 million shares and warrants for 1.331 million shares generated approximately $2.998 million net. Shares outstanding increased from 8.93 million at April 30 to 10.70 million at July 31. The five-year warrants have a $2.26 exercise price.
Material changes and outlook
- Management said consolidation of two manufacturing facilities into one was expected to reduce manufacturing expenses by approximately $1.0 million in fiscal 2012; cost of sales declined to 72% of revenue from 75%.
- XcelaSAN, a storage-caching product, remained under development. Technological feasibility was established in November 2010, and approximately $2.113 million of development costs had been capitalized by July 31. Capitalized costs are to be amortized to cost of sales once the product is generally released. Management expected capitalized software costs to decline in the following quarter.
- Management considered short-term liquidity needs satisfied based on offering proceeds, financing availability, and projected operating cash flows, including expected XcelaSAN sales. It cautioned that actual revenues may not meet projections. Long-term liquidity depends on profitable operations and positive cash flows.
- Risks noted include DRAM price and availability changes, demand for memory systems, competition, and delays in developing or commercializing products. The company also has foreign-currency exposure, primarily to the euro, and does not currently hedge with forward contracts. No material change to previously disclosed risk factors was reported.
- The company disclosed $1.878 million of future minimum operating lease payments as of April 30, 2011. No reportable legal proceedings or defaults were disclosed. A related party owned by an executive officer supplied inventory; purchases from it were approximately $1.35 million during the quarter.
Important facts to verify
- Confirm the issuer and filing: the text identifies Dataram Corporation, not U.S. Gold Corp.
- Confirm the intended reporting period: the statements cover the three months ended July 31, 2011, not a calendar first quarter.
- Review the equity offering and warrant terms, resulting dilution, and the related-party financing and inventory arrangements.
- Assess whether projected XcelaSAN sales and other operating cash flows support management’s liquidity assumptions, and monitor commercialization timing and capitalized development costs.
- Confirm the reported research and development expense treatment alongside capitalized software costs and the expected manufacturing savings.